Pre-treatment red cell index and metastasis status as independent predictors of overall survival in Jordanian breast cancer patients receiving chemotherapy.

Amjad Z Alrosan, Tahani Alwidyan, Ghaith B Heilat, Aseel O Rataan, Khaled Alrosan

Abstract read

In one paragraph

Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amjad Z AlrosanDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan.

Tahani AlwidyanDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan.

Ghaith B HeilatDepartment of General Surgery and Urology, Faculty of Medicine, The Jordan University of Science and Technology, Irbid 22110, Jordan.

Aseel O RataanDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.

Khaled AlrosanDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) poses a global health challenge, necessitating accessible prognostic biomarkers. Systemic inflammatory markers from complete blood counts, such as neutrophil-to-lymphocyte ratio (NLR) and red cell index (RCI), have shown prognostic potential. This retrospective study evaluated the prognostic significance of pre-treatment NLR and RCI for overall survival (OS) in 144 Jordanian BC patients (KAUH, 2011-2025) undergoing chemotherapy. Kaplan-Meier analysis revealed that high pre-treatment NLR (≥ 4.25) and high RCI (≥ 0.02) were significantly associated with shorter OS. Multivariate Cox regression identified elevated pre-treatment RCI (≥ 0.02) and metastasis at diagnosis as independent predictors of increased mortality and worse OS. A significant association between high NLR and RCI values was also observed, suggesting a link between systemic inflammation and erythrocytic dysregulation. In conclusion, pre-treatment RCI and metastasis are strong independent predictors of OS in this cohort, with RCI demonstrating substantial prognostic value.

Indexed as

Breast cancerChemotherapyComplete blood countNeutrophil-to-lymphocyte ratioOverall survivalPrognostic biomarkerRed cell index

Identifiers

PMID40613082

DOI10.1016/j.toxrep.2025.102077

PMCPMC12221659

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.